Medical device maker TransMedics Q3 revenue misses estimates

TransMedics

29/10/2025 20:50

Overview

TransMedics Q3 revenue grows 32% yr/yr but misses analyst expectations

Net income for Q3 rises to $24.3 mln, reflecting strong operational performance

Company announces collaboration with Mercedes-Benz for organ transport in Italy

Outlook

TransMedics raises 2025 revenue guidance to $595 mln-$605 mln

Company aims to end 2025 strongly and prepare for growth in 2026

TransMedics plans to deploy Mercedes-Benz vehicles for organ transport in Italy

Result Drivers

OCS UTILIZATION - Revenue growth driven by increased utilization of Organ Care System, particularly in Liver and Heart through NOP

R&D INVESTMENT - Operating expenses rose due to increased R&D investment and organizational growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$143.80 mln
$145.20 mln (10 Analysts)
Q3 Net Income
$24.30 mln
Q3 Gross Margin
59%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Transmedics Group Inc is $146.50, about 11.5% above its October 28 closing price of $129.71

The stock recently traded at 49 times the next 12-month earnings vs. a P/E of 62 three months ago

Press Release: ID:nPn7L926Za

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)